In recent years progress has been made in developing cancer immunotherapies that target specific aspects of an individual’s tumour.more
Introducing cancer immunotherapy
Immunotherapy at Roche
Roche are leading in cancer immunotherapy through innovative research, including immune profiling, with the goal to develop treatment tailored to individuals.more
Beyond the immunity cycle
Roche’s scientists are leading pioneers in immune biology and cancer research, which is resulting in innovative and personalised treatment options in cancer.
Collaboration in research
Cancer remains one of the leading causes of death worldwide, but world-class research provides hope.more
About bladder cancer
Bladder cancer is one of the top ten most common cancers in the world.more
Bladder cancer: the symptoms you shouldn’t ignore
One patient shares his experience being diagnosed with a disease he knew nothing about.more
Changing the colorectal cancer story
Two days after being admitted to hospital with stomach pains, Eve Bukowski woke up to the news we all fear.more
About renal cell carcinoma
Renal cell carcinoma is the most common form of kidney cancer, accounting for approximately 90% of casesmore
About colorectal cancer
Despite treatments improving in the early lines of therapy, in advanced colorectal cancer options remain limited.more
A pocket guide to interpreting data
Obtain simple definitions of clinical terms with our pocket guide to interpreting data.
Learn about some of the different ways we can harness the power of our immune system to fight cancer.more
Linking T-cells and cancer cells
When the body’s own immune system fails, T-cell bispecific antibodies help T-cells spring back into action and attack cancer cells.
CEO on cancer immunotherapy
Roche CEO Severin Schwan talks about our commitment and leadership in this exciting field.
Rewriting the book on immunotherapy
Learn how biomarkers take the stage in helping doctors diagnose cancer.more
The PD-L1 pathway
The role of the immune system is to protect the body from foreign invaders. PD-L1 can help tumour cells evade the immune surveillance.
Unleashing the T-Cell army
Learn how our research and development team managed to separate 200 known cancer types into three primary immune profiles.
Ever wondered how patient outcomes are measured in clinical trials?
Today, approaches that measure cancer treatment are more comprehensive – they look to extend patients’ lives and maintain quality of life.more